Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6,456Revenue $M759Net Margin (%)47.2Z-Score16.9
Enterprise Value $M5,822EPS $8.1Operating Margin %55.8F-Score5
P/E(ttm))19.4Cash Flow Per Share $4.6Pre-tax Margin (%)56.9Higher ROA y-yN
Price/Book6.110-y EBITDA Growth Rate %0Quick Ratio3.9Cash flow > EarningsN
Price/Sales9.25-y EBITDA Growth Rate %56.8Current Ratio4.4Lower Leverage y-yY
Price/Cash Flow10.1y-y EBITDA Growth Rate %26.9ROA % (ttm)25.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)32.2Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M44.8ROI % (ttm)31.2Gross Margin Increase y-yY

Gurus Latest Trades with NYSE:TARO

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

NYSE:TARO is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NYSE:TARO: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NYSE:TARO :

    Quarterly/Annual Reports about NYSE:TARO:

      News about NYSE:TARO:

      Articles On GuruFocus.com
      Pharmaceutical Industry on the Cusp Of Change Jun 02 2014 
      Teva Pharmaceutical (TEVA) Dividend Stock Analysis Jun 28 2013 
      taro pharma could double Aug 26 2012 
      What do people think of TARO Aug 26 2012 
      TARO Shares are Mispriced Compared to Competitors Like Perrigo and Teva May 10 2012 
      Sun Pharmaceutical Extends Tender Offer for Taro Dec 19 2008 

      More From Other Websites
      No related articles found.

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK